论文信息 - Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) - 字舞流文

Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

H. Wakelee | C. Liang | C. Lovly | J. Infante | J. Gibbons | J. Gockerman | L. Horn | C. Carter | K. Reckamp | G. Blumenschein | G. Dukart | K. Harrow